Cell and Gene Therapies
Targeting Vascular Disease
Ambulero, Inc is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease.
Our cell therapy program uses stromal cells engineered to express a cell adhesion molecule called E-selectin. We call these “supercharged” stromal cells because in animal models they promote exceptional tissue repair. For our gene therapy program, we simplify the approach by using established gene therapy vectors to give injured tissues the E-selectin molecule directly.
Ambulero is developing a pipeline of candidate regenerative products engineered to provide a new approach for healing tissues damaged by vascular disease. We are developing two treatment modalities: one that delivers E-selectin as part of an engineered stromal cell (“Supercharged MSCs”) and the other delivering E-selectin as a gene therapy (AAV) vector.
September 10, 2023
AMBULERO IS HEADING TO THE BIG APPLE! We’ve been selected to participate in the Endless Frontier Labs (EFL) of the NYU/Stern School of Business for the 2023-2024 academic year!The EFL offers a nine-month program to accelerate early-stage company success through a goals-oriented mentorship program. And it’s our chance to give back by showing the next generation of NYU/Stern business leaders how we are advancing new cell and gene therapies to treat severe vascular disease.
NEW BUSINESS DEVELOPMENT
We believe our approach for repairing tissues damaged by vascular disease can offer patients new hope in the fight against vascular disease. Our first indication is a rare form of vascular ischemia that predominately strikes young patients and for which there is no satisfactory standard of care for many except limb amputation.
As Ambulero develops its cell and gene therapy products for treatment of selected vascular disease indications, we also seek research and partnering opportunities to maximize the value of our gene and cell therapies.
For questions or inquiries about collaborations and partnering, please contact:
Chief Operating Officer